In short
This article discusses clinical trials investigating the use of GSKVx000000008866, a novel drug candidate, for the treatment of chronic hepatitis B (CHB). These trials aim to assess the safety, efficacy, and immune response of GSKVx000000008866 alone or in combination with other therapies in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy. The studies explore different dosing regimens and administration methods to determine the most effective approach for managing this persistent viral infection.
At a glance
- Study Type
- Phase I/II and Phase II clinical trials
- Participant Profile
- Adults (18-65 years) with chronic hepatitis B on stable nucleos(t)ide analogue therapy
- Intervention
- GSKVx000000008866 alone or in combination with other investigational therapies
- Administration
- Intramuscular injection
- Primary Objectives
- Safety, efficacy, and immune response assessment
- Key Efficacy Measures
- HBsAg reduction, HBsAg loss, anti-HBs seroconversion, HBV DNA suppression
- Safety Monitoring
- Adverse events, laboratory abnormalities, serious adverse events
- Immunogenicity Assessment
- Anti-HBc and anti-HBs antibodies, HBV-specific T-cell responses
- Duration
- Variable, with long-term follow-up for safety and efficacy
Overview of GSKVX000000008866
GSKVX000000008866 is an investigational therapeutic vaccine being developed by GlaxoSmithKline Biologicals for the treatment of chronic hepatitis B (CHB). This vaccine is designed to stimulate the immune system to fight against the hepatitis B virus (HBV) in patients who are already infected and on stable nucleos(t)ide analogue (NA) therapy.
Mechanism of Action
The vaccine works through a novel approach combining different components:
- Viral vector vaccines: These include ChAd155-hIi-HBV (an adenovirus-based vector) and MVA-HBV (a modified vaccinia Ankara-based vector). These vectors are designed to deliver HBV antigens to stimulate the immune system.
- Adjuvanted protein vaccines: These contain HBc (hepatitis B core) and HBs (hepatitis B surface) antigens combined with an adjuvant called AS01B-4. Adjuvants help enhance the immune response to the vaccine.
This combination approach aims to induce both antibody and T-cell responses against HBV, potentially leading to better control or clearance of the virus.
Clinical Trials
GSKVX000000008866 is currently being studied in clinical trials to evaluate its safety, efficacy, and immune response in patients with chronic hepatitis B. Two notable studies include:
- A Phase I/II trial (Study TH HBV VV-001) evaluating different dosing regimens and combinations of the viral vector and adjuvanted protein vaccines.
- A Phase II trial (Study TH HBV ASO-001) investigating the sequential treatment of an antisense oligonucleotide (ASO) followed by GSKVX000000008866.
Potential Efficacy
The clinical trials aim to assess the efficacy of GSKVX000000008866 through several key measures:
- Reduction in hepatitis B surface antigen (HBsAg) levels
- HBsAg loss and seroconversion (development of antibodies against HBsAg)
- Suppression of HBV DNA levels
- Induction of HBV-specific immune responses
The goal is to achieve a sustained virologic response (SVR), defined as HBsAg levels below the lower limit of quantification and undetectable HBV DNA. This could potentially lead to functional cure of chronic hepatitis B.
Safety Profile
The safety of GSKVX000000008866 is being closely monitored in clinical trials. Key safety assessments include:
- Occurrence of adverse events (AEs) and serious adverse events (SAEs)
- Injection site reactions (such as redness, pain, and swelling)
- Systemic reactions
- Laboratory abnormalities
- Potential immune-mediated disorders (pIMDs)
As with any investigational treatment, patients should be aware that unexpected side effects may occur.
Administration
GSKVX000000008866 is administered as an intramuscular injection. The exact dosing schedule and number of injections may vary depending on the specific regimen being studied. In some trials, it is given as a series of injections over several months.
Future Prospects
If successful in clinical trials, GSKVX000000008866 could potentially offer a new therapeutic option for patients with chronic hepatitis B. The goal is to achieve better control of the virus and possibly even functional cure, which would be a significant advancement in the treatment of this chronic infection.
It's important to note that GSKVX000000008866 is still in the investigational stage, and more research is needed to fully understand its efficacy and safety profile. Patients with chronic hepatitis B should continue to follow their current treatment plans and consult with their healthcare providers about potential new therapies.